Oragenics Inc (OGEN)
Oragenics, Inc. is a development-stage biotechnology company focused on researching and developing nasal delivery pharmaceutical therapies for neurological conditions and infectious diseases in the United States. Its lead candidate is ONP-002, a fully synthetic neurosteroid designed to cross the blood-brain barrier and target swelling, oxidative stress, and inflammation in the treatment of mild traumatic brain injury. The company, formerly known as Oragen, Inc., was incorporated in 1996 and is headquartered in Lakewood Ranch, Florida. Oragenics common stock trades on the New York Stock Exchange under the symbol OGEN.
Stock Summary Fair Value Profitability & Growth Quality & Risk Events & Dividends Market Outlook FAQ
Jump directly to the stock analysis sections supported by the latest available data.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Overall Financial Health | Dividend Yield | Next Earnings Date | Price-to-Book Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NYSE-OGEN
|
$0.68
|
30.0% Upside
|
Undervalued
|
Not available
|
Not available
|
Fair
|
0.0%
|
November 12, 2026
|
0.6x
|
2.346 M
|
-1.522 M
|
0.0%
|
98.1%
|
-140.4
|
101.2%
|
